HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. (October 2017)

• Record Type: Journal Article
• Authors: Caocci, Giovanni; Greco, Marianna; Arras, Marcella; Cusano, Roberto; Orrù, Sandro; Martino, Bruno; Abruzzese, Elisabetta; Galimberti, Sara; Mulas, Olga; Trucas, Marcello; Littera, Roberto; Lai, Sara; Carcassi, Carlo; La Nasa, Giorgio
• Is Part Of: Leukemia research. Volume 61(2017:Oct.)
• Page Start: 1
• Page End: 5
• Publication Date: 2017-10
• Subjects: Chronic myeloid leukemia -- HLA-G -- Molecular response; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2017.08.005
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: HLA-G molecules play a role in cancer immune-editing and NK cell inhibition. Lower event free survival in CML is associated to higher level of HLA-G. Deeper molecular response in CML is associated to lower level of HLA-G. HLA-G could represent a new useful predictive immune biomarker in CML. HLA-G is an innovative target for immune-mediated treatment approaches. Abstract: The human leukocyte antigen-G (HLA-G) gene encodes a tolerogenic protein known to promote tumor immune-escape. We investigated HLA-G polymorphisms and soluble molecules (sHLA-G) in 68 chronic myeloid leukemia (CML) patients. Patients with G*01:01:01 or G*01:01:02 allele had higher value of sHLA-G compared to G*01:01:03 (109.2 ± 39.5 vs 39.9 ± 8.8 units/ml; p = 0.03), and showed lower event free survival (EFS) (62.3% vs 90.0%; p = 0.02). The G*01:01:03 allele was associated with higher rates and earlier achievement of deep molecular response (MR) 4.5 (100% vs 65%, median of 8 vs 58 months, p = 0.001). HLA-G alleles with higher secretion of sHLA-G seem associated with lower EFS, possibly because of an inhibitory effect on the immune system. Conversely, lower levels of sHLA-G promoted achievement of MR 4.5, suggesting increased cooperation with immune system.